Hepatology News
| Aug 26, 2010 – SOURCE: Journal of Clinical Virology | |||
 |
|
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient | |
| INTRODUCTION: The efficacy of antiviral therapy with pegylated interferon (PEGIFN) plus ribavirin (RBV) in patients with HIV and hepatitis C virus (HCV) coinfection is limited. Intravenous silibinin (ivSIL), a milk thistle extract with proven antiviral ef | |||
| Aug 26, 2010 – SOURCE: American Journal of Nephrology | |||
|
|
Hepatitis C Increases the Risk of Progression of Chronic Kidney Disease in Patients with Glomerulonephritis | |
| Background/Aims: We have shown that hepatitis C does not increase the risk of developing chronic kidney disease (CKD), but it is not known if hepatitis C worsens progression of existing CKD. Methods: We retrospectively identified patients with primary glo | |||
| Aug 26, 2010 – SOURCE: International Journal of Gynecology & Obstetrics | |||
|
|
Pattern of hepatitis virus infection among pregnant women and their newborns at the Women's Health Center of Assiut University, Upper Egypt | |
| OBJECTIVE: To determine the prevalence, risk factors, and rate of vertical transmission of HBV and/or HCV infection among pregnant women in Upper Egypt, and assess the preventive efficacy of administering hepatitis B immunoglobulin and vaccine to newborns | |||
| Aug 26, 2010 – SOURCE: Journal of Gastroenterology | |||
|
|
Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus | |
| BACKGROUND: Noninvasive risk factors are required for predicting the development of hepatocellular carcinoma (HCC) not only in patients with cirrhosis but also in those with chronic hepatitis who are infected with hepatitis C virus (HCV). METHODS: A total | |||
| Aug 26, 2010 – SOURCE: DGNews | |||
|
|
FDA: Risk of Transmitting Bloodborne Pathogens via Fingerstick Blood Testing Devices | |
| ROCKVILLE, Md -- August 26, 2010 -- The US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have noted a progressive increase in the reports of bloodborne infection transmission over the past 10 to 15 years (prim | |||
| Aug 26, 2010 – SOURCE: Gastroenterology | |||
|
|
Variants in IL28B in liver recipients and donors correlate with response to peginterferon and ribavirin therapy for recurrent hepatitis C | |
| BACKGROUND&AIMS:: Patients with hepatitis C virus (HCV)-related liver disease frequently receive orthotopic liver transplantation (OLT), but recurrent hepatitis C is still a major cause of morbidity. Patients are treated with peg-interferon and ribavirin | |||
| Aug 26, 2010 – SOURCE: Journal of Ultrasound in Medicine | |||
|
|
Role of contrast-enhanced ultrasonography in primary hepatic lymphoma | |
| OBJECTIVE: Ultrasonography is the first examination performed for screening of hepatocellular carcinoma (HCC); contrast-enhanced ultrasonography (CEUS) can help discriminate between HCC and other lesions. Primary hepatic lymphoma (PHL), even if rare, shou | |||
| Aug 25, 2010 – SOURCE: Antiviral Research | |||
|
|
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48hours after the start of treatment with pegylated interferon and ribavirin | |
| The combination of pegylated interferons (PEG-IFNs) and ribavirin represents the standard of care for the treatment of chronic HCV-infected patients, yet with a success rate around 50% in genotypes -1 and -4, high costs and side effects. Therefore, early | |||
| Aug 25, 2010 – SOURCE: BMC Gastroenterology | |||
|
|
Infection with HIV and HCV enhances the release of fatty acid synthase into circulation: evidence for a novel indicator of viral infection | |
| ABSTRACT: BACKGROUND: Fatty acid synthase (FASN) is an enzyme synthesized by the liver and plays an important role in lipogenesis. The present study aimed to investigate whether serum FASN concentration may provide a direct link between HIV and/or HCV vir | |||
| Aug 25, 2010 – SOURCE: Transplant International | |||
|
|
Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review | |
| Abstract Noninvasive tests (NIT) for evaluation of hepatic fibrosis have not been evaluated extensively in liver transplantation. We systematically reviewed the literature regarding NIT after liver transplantation. We identified 14 studies evaluating NIT | |||
